New tricks for old dogmas: Optogenetic and designer receptor insights for Parkinson's disease

Brain Research

Volumn 1511, Issue , 2013, Pages 153-163

  Vazey, Elena M ^a   Aston Jones, Gary ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Basal ganglia; Dopamine; DREADD; Non motor; Norepinephrine; Optogenetic; Parkinson's disease; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE; OPSIN; VIRUS VECTOR;

BASAL GANGLION; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; CORPUS STRIATUM; DEMENTIA; GENE THERAPY; HUMAN; INTRACELLULAR SIGNALING; NERVE TRACT; NERVE TRANSPLANTATION; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPTOGENETICS; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SUBTHALAMIC NUCLEUS; TRANSGENICS;

BASAL GANGLIA; DESIGNER DRUGS; HUMANS; NEURAL PATHWAYS; OPTOGENETICS; PARKINSON DISEASE;

PARKINSONIA;

EID: 84879839702     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.01.021     Document Type: Review

References (90)

1. D. Aarsland, J.P. Larsen, E. Tandberg, and K. Laake Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study J. Am. Geriatrics Soc. 48 2000 938 942
2. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends in Neurosci. 12 1989 366 375
3. G.M. Alexander, S.C. Rogan, A.I. Abbas, B.N. Armbruster, Y. Pei, J.A. Allen, R.J. Nonneman, J. Hartmann, S.S. Moy, M.A. Nicolelis, J.O. McNamara, and B.L. Roth Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors Neuron 63 2009 27 39
4. L. Alvarez, R. Macias, J. Guridi, G. Lopez, E. Alvarez, C. Maragoto, J. Teijeiro, A. Torres, N. Pavon, M.C. Rodriguez-Oroz, L. Ochoa, H. Hetherington, J. Juncos, M.R. DeLong, and J.A. Obeso Dorsal subthalamotomy for Parkinson's disease Movement Disord.: Off. J. Movement Disord. Soc. 16 2001 72 78
5. L. Alvarez, R. Macias, N. Pavon, G. Lopez, M.C. Rodriguez-Oroz, R. Rodriguez, M. Alvarez, I. Pedroso, J. Teijeiro, R. Fernandez, E. Casabona, S. Salazar, C. Maragoto, M. Carballo, I. Garcia, J. Guridi, J.L. Juncos, M.R. DeLong, and J.A Obeso Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months J. Neurol.; Neurosurg. & Psychiatry 80 2009 979 985
6. B.N. Armbruster, X. Li, M.H. Pausch, S. Herlitze, and B.L. Roth Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand Proc. Natl. Acad. Sci. U S A 104 2007 5163 5168
7. G. Aston-Jones, and J.D. Cohen An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance Annu. Rev. Neurosci. 28 2005 403 450
8. D. Atasoy, Y. Aponte, H.H. Su, and S.M. Sternson A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping J. Neurosci.: Off. J. Soc. Neurosci. 28 2008 7025 7030
9. J.G. Bernstein, and E.S. Boyden Optogenetic tools for analyzing the neural circuits of behavior Trends Cognitive Sci. 15 2011 592 600
10. W. Birkmayer, and O. Hornykiewicz The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia Wiener klinische Wochenschrift. 73 1961 787 788
11. D.L. Braff, N.R. Swerdlow, and M.A. Geyer Symptom correlates of prepulse inhibition deficits in male schizophrenic patients Am. J. Psychiatry 156 1999 596 602
12. A. Carlsson, M. Lindqvist, T. Magnusson, and B. Waldeck On the presence of 3-hydroxytyramine in brain Science 127 1958 471
13. M.E. Carter, O. Yizhar, S. Chikahisa, H. Nguyen, A. Adamantidis, S. Nishino, K. Deisseroth, and L. de Lecea Tuning arousal with optogenetic modulation of locus coeruleus neurons Nat. Neurosci. 13 2010 1526 1533
14. V. Chan-Palay, and E. Asan Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression J. Comp. Neurol. 287 1989 373 392
15. Y. Chudasama, and T.W. Robbins Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans Biol. Psychol. 73 2006 19 38
16. B.R. Conklin, E.C. Hsiao, S. Claeysen, A. Dumuis, S. Srinivasan, J.R. Forsayeth, J.M. Guettier, W.C. Chang, Y. Pei, K.D. McCarthy, R.A. Nissenson, J. Wess, J. Bockaert, and B.L. Roth Engineering GPCR signaling pathways with RASSLs Nat. Methods 5 2008 673 678
17. Cope, Z.A.; Vazey, E.M.; Moorman, D.E.; Floresco, S.B.; Aston-Jones, G.; 2012. Optogenetically mediated tonic stimulation of locus coeruleus improves maintenance of novel strategies on extradimensional shifts. Program No. 208.08. Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2012. Online
18. K. Deisseroth Optogenetics Nat. Methods 8 2011 26 29
19. K. Del Tredici, U. Rub, R.A. De Vos, J.R. Bohl, and H. Braak Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61 2002 413 426
20. N.L. Diaz, and C.H. Waters Current strategies in the treatment of Parkinson's disease and a personalized approach to management Expert Rev. Neurother. 9 2009 1781 1789
21. D.W. Dickson, H. Braak, J.E. Duda, C. Duyckaerts, T. Gasser, G.M. Halliday, J. Hardy, J.B. Leverenz, K. Del Tredici, Z.K. Wszolek, and I. Litvan Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria Lancet Neurol. 8 2009 1150 1157
22. D.W. Dickson, H. Fujishiro, C. Orr, A. DelleDonne, K.A. Josephs, R. Frigerio, M. Burnett, J.E. Parisi, K.J. Klos, and J.E. Ahlskog Neuropathology of non-motor features of Parkinson disease Parkinsonism & Related Disord. 15 3 2009 S1 S5
23. S. Dong, S.C. Rogan, and B.L. Roth Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs Nat. Protoc. 5 2010 561 573
24. H. Ehringer, and O. Hornykiewicz Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin. Wochenschr. 38 1960 1236 1239
25. S.A. Factor, P.J. Feustel, J.H. Friedman, C.L. Comella, C.G. Goetz, R. Kurlan, M. Parsa, and R. Pfeiffer Longitudinal outcome of Parkinson's disease patients with psychosis Neurology 60 2003 1756 1761
26. M.S. Farrell, and B.L. Roth Pharmacosynthetics: reimagining the pharmacogenetic approach Brain Res. 2012, 10.1016/j.brainres.2012.09.043, this issue
27. S.M. Ferguson, D. Eskenazi, M. Ishikawa, M.J. Wanat, P.E. Phillips, Y. Dong, B.L. Roth, and J.F. Neumaier Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization Nat. Neurosci. 14 2011 22 24
28. M. Figueiredo, S. Lane, F. Tang, B.H. Liu, J. Hewinson, N. Marina, V. Kasymov, E.A. Souslova, D.M. Chudakov, A.V. Gourine, A.G. Teschemacher, and S. Kasparov Optogenetic experimentation on astrocytes Exp. Physiol. 96 2011 40 50
29. C.R. Freed, W. Zhou, and R.E. Breeze Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials Neurotherapeutics 8 2011 549 561
30. J.H. Friedman Parkinson's disease psychosis 2010: a review article Parkinsonism & related disorders 16 2010 553 560
31. Geyer, M. A. and Swerdlow, N. R. 2001. Measurement of Startle Response, Prepulse Inhibition, and Habituation. Current Protocols in Neuroscience. Chapet 8, unit 87. (8.7.1-8.7.15)
32. D.S. Goldstein, P. Sullivan, C. Holmes, I.J. Kopin, M.J. Basile, and D.C. Mash Catechols in post-mortem brain of patients with Parkinson disease Eur. J. Neurol.: Off. J. Eur. Fed. Neurol. Soc. 18 2011 703 710
33. A.V. Gourine, V. Kasymov, N. Marina, F. Tang, M.F. Figueiredo, S. Lane, A.G. Teschemacher, K.M. Spyer, K. Deisseroth, and S. Kasparov Astrocytes control breathing through pH-dependent release of ATP Science 329 2010 571 575
34. V. Gradinaru, M. Mogri, K.R. Thompson, J.M. Henderson, and K. Deisseroth Optical deconstruction of parkinsonian neural circuitry Science 324 2009 354 359
35. J.G. Greenfield, and F.D. Bosanquet The brain-stem lesions in Parkinsonism Journal of neurology, neurosurgery, and psychiatry 16 1953 213 226
36. J.M. Guettier, D. Gautam, M. Scarselli, I. Ruiz de Azua, J.H. Li, E. Rosemond, X. Ma, F.J. Gonzalez, B.N. Armbruster, H. Lu, B.L. Roth, and J Wess A chemical-genetic approach to study G protein regulation of beta cell function in vivo Proc. Natl. Acad. Sci. U S A 106 2009 19197 19202
37. C. Guigoni, I. Aubert, Q. Li, V.V. Gurevich, J.L. Benovic, S. Ferry, U. Mach, H. Stark, L. Leriche, K. Håkansson, B.H. Bioulac, C.E. Gross, P. Sokoloff, G. Fisone, E.V. Gurevich, B. Bloch, and E. Bezard Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors Parkinsonism & Relat. Disord. 11 2005 S25 S29
38. A. Gupta, V.L. Dawson, and T.M. Dawson What causes cell death in Parkinson's disease? Ann. Neurol. 64 2 2008 S3 15
39. C.H. Hawkes, K. Del Tredici, and H. Braak A timeline for Parkinson's disease Parkinsonism & Relat. Disord. 16 2010 79 84
40. E.C. Hirsch, S. Vyas, and S. Hunot Neuroinflammation in Parkinson's disease Parkinsonism & Relat. Disord. 18 1 2012 S210 S212
41. J. Janzen, D. Van 't Ent, A.W. Lemstra, H.W. Berendse, F. Barkhof, and E.M Foncke The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study J. Neurol. 259 2012 147 154
42. M.G. Kaplitt, A. Feigin, C. Tang, H.L. Fitzsimons, P. Mattis, P.A. Lawlor, R.J. Bland, D. Young, K. Strybing, D. Eidelberg, and M.J. During Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 369 2007 2097 2105
43. A.A. Kehagia, R.A. Barker, and T.W. Robbins Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease Lancet Neurol. 9 2010 1200 1213
44. A.V. Kravitz, B.S. Freeze, P.R. Parker, K. Kay, M.T. Thwin, K. Deisseroth, and A.C. Kreitzer Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry Nature 466 2010 622 626
45. A.V. Kravitz, L.D. Tye, and A.C. Kreitzer Distinct roles for direct and indirect pathway striatal neurons in reinforcement Nat. Neurosci. 15 2012 816 818
46. J.W. Langston The Parkinson's complex: parkinsonism is just the tip of the iceberg Ann. Neurol. 59 2006 591 596
47. Y. Lee, V.L. Dawson, and T.M. Dawson Animal models of Parkinson s disease: vertebrate genetics Cold Spring Harbor Perspect. Med. 2 2012 a009324
48. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
49. P.A. LeWitt, A.R. Rezai, M.A. Leehey, S.G. Ojemann, A.W. Flaherty, E.N. Eskandar, S.K. Kostyk, K. Thomas, A. Sarkar, M.S. Siddiqui, S.B. Tatter, J.M. Schwalb, K.L. Poston, J.M. Henderson, R.M. Kurlan, I.H. Richard, L. Van Meter, C.V. Sapan, M.J. During, M.G. Kaplitt, and A. Feigin AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial Lancet Neurol. 10 2011 309 319
50. D. Li, K. Hérault, E.Y. Isacoff, M. Oheim, and N. Ropert Optogenetic activation of LiGluR-expressing astrocytes evokes anion channel-mediated glutamate release J. Physiol. 590 2012 855 873
51. J. Lindeberg, D. Usoskin, H. Bengtsson, A. Gustafsson, A. Kylberg, S. Soderstrom, and T. Ebendal Transgenic expression of Cre recombinase from the tyrosine hydroxylase locus Genesis 40 2004 67 73
52. L. Madisen, T. Mao, H. Koch, J.M. Zhuo, A. Berenyi, S. Fujisawa, Y.W. Hsu, A.J. Garcia 3rd, X. Gu, S. Zanella, J. Kidney, H. Gu, Y. Mao, B.M. Hooks, E.S. Boyden, G. Buzsaki, J.M. Ramirez, A.R. Jones, K. Svoboda, X. Han, E.E. Turner, and H. Zeng A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing Nat. Neurosci. 15 2012 793 802
53. S.V. Mahler, E.M. Vazey, J. Kaufling, and G. Aston-Jones Just C NO to DREADDs: inhibition of ventral pallidum projection to ventral tegmental area blocks cue-triggered cocaine seeking Neuropsychopharmacol. 38 2012 S198 S313
54. N. Mallet, B. Ballion, C. Le Moine, and F. Gonon Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats J. Neurosci. 26 2006 3875 3884
55. K. McFarland, D.L. Price, and D.W. Bonhaus Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease Behav. Pharmacol. 22 2011 681 692
56. H.Y. Meltzer, R. Mills, S. Revell, H. Williams, A. Johnson, D. Bahr, and J.H. Friedman Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 35 2010 881 892
57. R. Meyers Surgical procedure for postencephalitic tremor, with notes on the physiology of premotor fibers Arch. Neurol. Psychiatry 44 1940 455 459
58. Murphy, S.L.; Xu, J.Q.; Kochanek, K.D.; 2012. Deaths: Preliminary data for 2010. National vital statistics reports. Vol. 60. National Center for Health Statistics, Hyattsville, MD.
59. S.G. Nair, N.S. Strand, and J.F. Neumaier DREADDing the lateral habenula: a review of methodological approaches for studying lateral habenula function Brain Res. 17 2012 01638-1
60. K. Nakajima, and J. Wess Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor Mol. Pharmacol. 82 2012 575 582
61. T. Nayyar, M. Bubser, M.C. Ferguson, M.D. Neely, J. Shawn Goodwin, T.J. Montine, A.Y. Deutch, and T.A. Ansah Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation Eur. J. Neurosci. 30 2009 207 216
62. C.B. Nemeroff Recent advances in the neurobiology of depression Psychopharmacol. Bull. 36 2 2002 6 23
63. J. Parkinson An Essay on the Shaking Palsy 1817 Whittingham and Rowland for Sherwood Needly and Jones, London
64. E. Peltekian, L. Garcia, and O. Danos Neurotropism and retrograde axonal transport of a canine adenoviral vector: a tool for targeting key structures undergoing neurodegenerative processes Mol. Ther. 5 2002 25 32
65. E.K. Perry, M. Curtis, D.J. Dick, J.M. Candy, J.R. Atack, C.A. Bloxham, G. Blessed, A. Fairbairn, B.E. Tomlinson, and R.H. Perry Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease Journal Neurol.; Neurosurg. Psychiatry 48 1985 413 421
66. E. Portales-Casamar, D.J. Swanson, L. Liu, C.N. De Leeuw, K.G. Banks, S.J. Ho Sui, D.L. Fulton, J. Ali, M. Amirabbasi, D.J. Arenillas, N. Babyak, S.F. Black, R.J. Bonaguro, E. Brauer, T.R. Candido, M. Castellarin, J. Chen, Y. Chen, J.C. Cheng, V. Chopra, T.R. Docking, L. Dreolini, C.A. D'Souza, E.K. Flynn, R. Glenn, K. Hatakka, T.G. Hearty, B. Imanian, S. Jiang, S. Khorasan-zadeh, I. Komljenovic, S. Laprise, N.Y. Liao, J.S. Lim, S. Lithwick, F. Liu, J. Liu, M. Lu, M. McConechy, A.J. McLeod, M. Milisavljevic, J. Mis, K. O'Connor, B. Palma, D.L. Palmquist, J.F. Schmouth, M.I. Swanson, B. Tam, A. Ticoll, J.L. Turner, R. Varhol, J. Vermeulen, R.F. Watkins, G. Wilson, B.K. Wong, S.H. Wong, T.Y. Wong, G.S. Yang, A.R. Ypsilanti, S.J. Jones, R.A. Holt, D. Goldowitz, W.W. Wasserman, and E.M. Simpson A regulatory toolbox of mini promoters to drive selective expression in the brain Proc. Natl. Acad. Sci. USA 107 2010 16589 16594
67. P.M. Rappold, and K. Tieu Astrocytes and therapeutics for Parkinson's disease Neurotherapeutics 7 2010 413 423
68. R.S. Ray, A.E. Corcoran, R.D. Brust, J.C. Kim, G.B. Richerson, E. Nattie, and S.M. Dymecki Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition Science 333 2011 637 642
69. T.W. Robbins, and A.F. Arnsten The neuropsychopharmacology of fronto-executive function: monoaminergic modulation Annu. Rev. Neurosci. 32 2009 267 287
70. Robertson, S.D.; Plummer, N.W.; De Marchena, J.; Jensen, P.; 2011. Genetic fate-mapping of the central noradrenergic system. Program No. 542.08. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online
71. S.M. Rothman, and M.P. Mattson Sleep disturbances in Alzheimer's and Parkinson's diseases Neuromol. Med. 14 2012 194 204
72. Salegio, E.A.; Samaranch, L.; Kells, A.P.; Mittermeyer, G.; San Sebastian, W.; Zhou, S.; Beyer, J.; Forsayeth, J.; Bankiewicz, K.S.; 2012. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther.
73. D. Smedley, E. Salimova, and N. Rosenthal Cre recombinase resources for conditional mouse mutagenesis Methods 53 2011 411 416
74. G.D. Stuber, T.S. Hnasko, J.P. Britt, R.H. Edwards, and A. Bonci Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate J. Neurosci.: Off. J. Soc. Neurosci. 30 2010 8229 8233
75. E.J. Sweger, K.B. Casper, K. Scearce-Levie, B.R. Conklin, and K.D. McCarthy Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes J. Neurosci.: Off. J. Soc. Neurosci. 27 2007 2309 2317
76. J. Tonnesen, C.L. Parish, A.T. Sorensen, A. Andersson, C. Lundberg, K. Deisseroth, E. Arenas, O. Lindvall, and M. Kokaia Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model PloS One 6 2011 e17560
77. N.X. Tritsch, J.B. Ding, and B.L. Sabatini Dopaminergic neurons inhibit striatal output through non-canonical release of GABA Nature 490 2012 262 266
78. E. Vazey, V. Hinson, A. Granholm, M. Eckert, and G. Jones Norepinephrine in neurodegeneration: a coerulean target J. Alzheimers Dis. Parkinsonism 2 2012 e114
79. Vazey, E.M.; Cope, Z.A.; Eckert, M.A.; Hinson,V.K.; Granholm, A.-C.; Floresco, S.B.; Aston-Jones, G.; 2011.Contributions of norepinephine and dopamine loss to cognitive in flexibility in a rat model of Parkinson's disease (Program No. 883.18. 2011). Society for Neuroscience. Program no.883.18. Neuroscience Meeting Planner Online, Washington, D.C. USA.
80. Vazey, E.M.; Aston-Jones, G.; 2012. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front. Behav. Neurosci. 6, number 00048, URL= http://www.frontiersin.org/Journal/Abstract.aspx?s= 99&name=behavioral-neuroscience&ART-DOI=10.3389/fnbeh.2012.00048.
81. Vazey, E.M.; Cope, Z.A.; Moorman, D.E.; Aston-Jones, G.; 2012b. Neuromodulation of the nucleus locus coeruleus: tools and techniques. Program No. 208.13. 2012. Society for Neuroscience. Neuroscience Meeting Planner Online, New Orleans, LA: Society for Neuroscience, 2012. Online.
82. T. Weber, K. Schonig, B. Tews, and D. Bartsch Inducible gene manipulations in brain serotonergic neurons of transgenic rats PLoS One 6 2011 e28283
83. D. Weintraub, S. Mavandadi, E. Mamikonyan, A.D. Siderowf, J.E. Duda, H.I. Hurtig, A. Colcher, S.S. Horn, S. Nazem, T.R. Ten Have, and M.B. Stern Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease Neurology 75 2010 448 455
84. T. Wichmann, M.R. DeLong, J. Guridi, and J.A. Obeso Milestones in research on the pathophysiology of Parkinson's disease Movement Disord.: Off. J. Movement Disord. Soc. 26 2011 1032 1041
85. A.W. Willis, M. Schootman, N. Kung, B.A. Evanoff, J.S. Perlmutter, and B.A. Racette Predictors of survival in patients with Parkinson disease Arch. Neurol. 69 2012 601 607
86. I.B. Witten, S.C. Lin, M. Brodsky, R. Prakash, I. Diester, P. Anikeeva, V. Gradinaru, C. Ramakrishnan, and K. Deisseroth Cholinergic interneurons control local circuit activity and cocaine conditioning Science 330 2010 1677 1681
87. I.B. Witten, E.E. Steinberg, S.Y. Lee, T.J. Davidson, K.A. Zalocusky, M. Brodsky, O. Yizhar, S.L. Cho, S. Gong, C. Ramakrishnan, G.D. Stuber, K.M. Tye, P.H. Janak, and K. Deisseroth Recombinase-driver rat lines: tools, techniques, and optogenetic application to dopamine-mediated reinforcement Neuron 72 2011 721 733
88. E. Wolters Non-motor extranigral signs and symptoms in Parkinson's disease Parkinsonism Relat. Disord. 15 3 2009 S6 12
89. O. Yizhar, L.E. Fenno, T.J. Davidson, M. Mogri, and K. Deisseroth Optogenetics in neural systems Neuron 71 2011 9 34
90. S. Zhao, J.T. Ting, H.E. Atallah, L. Qiu, J. Tan, B. Gloss, G.J. Augustine, K. Deisseroth, M. Luo, A.M. Graybiel, and G. Feng Cell type-specific channelrhodopsin-2 transgenic mice for optogenetic dissection of neural circuitry function Nat. Methods 8 2011 745 752